0001178913-18-000726.txt : 20180228
0001178913-18-000726.hdr.sgml : 20180228
20180228161227
ACCESSION NUMBER: 0001178913-18-000726
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180227
FILED AS OF DATE: 20180228
DATE AS OF CHANGE: 20180228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stuart Iain
CENTRAL INDEX KEY: 0001727756
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 18651260
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
zk1821309.xml
OWNERSHIP DOCUMENT
X0306
4
2018-02-27
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727756
Stuart Iain
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
REHOVOT
L3
7670402
ISRAEL
0
1
0
0
SVP R&D
Ordinary Shares
2018-02-27
4
A
0
10000
0.00
A
37000
D
Options
6.35
2018-02-27
4
A
0
30000
6.35
A
2028-02-27
Ordinary Shares
30000
30000
D
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 27,000 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security and (ii) the 10,000 ordinary shares sub-ject to unvested restricted share units granted on February 27, 2018 and first reported on this Form 4.
Each option represents a contingent right to purchase one ordinary share of the issuer.
The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
/s/ Ilan Hadar as attorney-in-fact for Iain Stuart
2018-02-28